Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Other Non-Current Assets (2018 - 2025)

X4 Pharmaceuticals' Other Non-Current Assets history spans 8 years, with the latest figure at $692000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 66.73% year-over-year to $692000.0; the TTM value through Dec 2025 reached $692000.0, down 66.73%, while the annual FY2025 figure was $692000.0, 66.73% down from the prior year.
  • Other Non-Current Assets reached $692000.0 in Q4 2025 per XFOR's latest filing, down from $2.0 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $3.0 million in Q1 2025 to a low of $692000.0 in Q4 2025.
  • Average Other Non-Current Assets over 5 years is $1.7 million, with a median of $1.8 million recorded in 2021.
  • The largest YoY upside for Other Non-Current Assets was 101.94% in 2025 against a maximum downside of 66.73% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $1.7 million in 2021, then dropped by 28.9% to $1.2 million in 2022, then increased by 17.22% to $1.4 million in 2023, then soared by 44.85% to $2.1 million in 2024, then crashed by 66.73% to $692000.0 in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Other Non-Current Assets are $692000.0 (Q4 2025), $2.0 million (Q3 2025), and $2.4 million (Q2 2025).